Published:
Alzheimer's Disease Research

From Schizophrenia to Alzheimer's: Understanding the KarXT Clinical Trials

Could a breakthrough drug originally approved for schizophrenia help address some of the most challenging symptoms of Alzheimer’s disease? Join Dr. Paul Newhouse for a discussion on the emerging science behind KarXT (now FDA-approved for schizophrenia as Cobenfy). Dr. Newhouse will review active Phase 3 clinical trial programs—including MINDSET, ADEPT, and ADAGIO—and explain how researchers are investigating the effects of KarXT on cognitive impairment, psychosis, and agitation associated with Alzheimer’s disease. Discover what these global studies mean for families, what the science shows so far, and how caregivers can explore clinical trial participation opportunities.

Watch Episode

Transcript

Sponsored by:

Biogen blue logo
Eli Lilly logo
Genentech logo

About BrightFocus Foundation

BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $330 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.

Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.

Share this post